FDA Fast-Tracks Experimental Psychedelic Drugs for Mental Health Treatment
The Food and Drug Administration (FDA) has granted expedited review for three experimental psychedelic drugs intended to treat major depression and post-traumatic stress disorder (PTSD). This decision reflects a notable policy shift under the Trump administration towards approving treatments with psychoactive effects. The announcement follows closely on the heels of the Justice Department’s move to relax regulations pertaining to state-licensed medical marijuana.
The specific companies benefiting from priority vouchers for these FDA reviews have not been disclosed, as such evaluations typically extend over several months. However, it is anticipated that two companies will soon submit applications to use psilocybin as a treatment for major depressive disorder, particularly for cases resistant to conventional therapies. Meanwhile, another unnamed firm is investigating a PTSD treatment known as methylone, which shares similarities with MDMA.
FDA Commissioner Marty McCulley expressed optimism regarding these experimental drugs, stating in a press release that they “have the potential to address our nation’s mental health crisis, including conditions such as treatment-resistant depression, alcoholism, and other serious mental health and substance abuse disorders.”
In an interview with NBC News, McCulley indicated that the accelerated application process could lead to the approval of the first psychedelic drug by the end of the summer, marking a significant milestone for mental health treatment options.
The FDA’s Priority Voucher Program, which commenced in June 2025, aims to expedite the review process for urgently needed medications. This initiative has the potential to reduce the standard approval timeline from a year to just several months, significantly hastening access to critical therapies.
However, critics of the program voice concerns, suggesting it was implemented without sufficient Congressional oversight. They warn that allowing companies to potentially make financial contributions to the government in exchange for priority vouchers could compromise trust in the FDA’s regulatory integrity.
Research into psychedelics remains limited in the U.S., as many of these substances are still classified as illegal. Evidence regarding their effects is largely anecdotal, drawn from studies conducted in other countries. Recently, President Trump signed an executive order to bolster U.S.-led psychedelic research, a step welcomed by experts in the field.
Dr. Peg Nopoulos, chair of the Department of Psychiatry at the University of Iowa, expressed her enthusiasm for the advancing research landscape. She highlighted her earlier study that compared the effects of psilocybin and ketamine on alcohol use disorder, noting that both compounds can induce psychedelic experiences. “These are powerful drugs,” Dr. Nopoulos stated. “While I have witnessed their life-saving potential, I insist that scientific backing must determine their approval based on safety and efficacy.”
On Friday, the FDA’s actions also opened the door for researchers to investigate ibogaine, another psychedelic, for the first time in the U.S. Miami-based Demerex NB is set to study noribogaine hydrochloride, a derivative of ibogaine, as a potential remedy for alcohol use disorder. According to the National Institute on Alcohol Abuse and Alcoholism, around 28 million Americans, or one in ten, struggle with alcohol-related issues. Importantly, noribogaine is not associated with the intense, prolonged highs often linked to ibogaine itself.
